|
Published by: GBI Research
Published: Nov. 9, 2012 - 70 Pages
Table of Contents- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Parenteral Nutrition Market to 2018 - Introduction
- 3 Parenteral Nutrition Market to 2018 - Overview
- 3.1 Clinical Nutrition
- 3.1.1 Enteral Nutrition
- 3.1.2 Parenteral Nutrition
- 4 Parenteral Nutrition Market to 2018 - Market Characterization and Forecasts
- 4.1 Revenue Forecasts
- 4.2 Parenteral Nutrition Market Drivers
- 4.2.1 Increase in the Incidence of Diseases such as Cancer, AIDS and GI Disorders that Require Nutrition Support
- 4.2.2 Increase in the Elderly Population will Drive PN Market Growth
- 4.2.3 The Home Parenteral Nutrition Sector will Witness Strong Market Growth
- 4.3 Parenteral Nutrition Market Restraints
- 4.3.1 Reimbursement Regulations will Hinder Market Growth in the US
- 4.3.2 Increasing Preference for Enteral Nutrition will Restrain Market Growth
- 4.3.3 Increasing Preference for Multi-chamber Bags Decreases Cost of Therapy
- 5 Parenteral Nutrition Market to 2018 - Geographical Landscape
- 5.1 Revenues by Geographical Segmentation
- 5.2 The US
- 5.2.1 Sales Value
- 5.2.2 Nutrient Market Segmentation
- 5.2.3 Key Products
- 5.3 Top Five Countries in Europe
- 5.3.1 Sales Value
- 5.3.2 Nutrient Market Segmentation
- 5.3.3 Key Products
- 5.4 Japan
- 5.4.1 Sales Value
- 5.4.2 Nutrient Market Segmentation
- 5.4.3 Key Products
- 6 Parenteral Nutrition Market to 2018 - Nutrient Market Segmentation
- 6.1 Overview
- 6.2 Amino Acids Market
- 6.2.1 Global Sales Value
- 6.2.2 Sales Value by Geography
- 6.3 Lipids Market
- 6.3.1 Global Sales Value
- 6.3.2 Sales Value by Geography
- 6.4 Carbohydrates Market
- 6.4.1 Global Sales Value
- 6.4.2 Sales Value by Geography
- 6.5 Additives Market
- 6.5.1 Global Sales Value
- 6.5.2 Sales Value by Geography
- 7 Parenteral Nutrition Market - Marketed Products
- 7.1 Baxter International Inc.
- 7.1.1 OLIMEL
- 7.1.2 Clinimix
- 7.1.3 ClinOleic 20%
- 7.1.4 Clinisol 15%
- 7.2 B. Braun Melsungen AG
- 7.2.1 NuTRIflex System
- 7.2.2 Lipofundin
- 7.2.3 Aminoplasmal
- 7.2.4 FreAmine III
- 7.3 Fresenius Kabi AG
- 7.3.1 Intralipid
- 7.3.2 SmofKabiven
- 7.3.3 Dipeptiven
- 7.3.4 Omegaven
- 7.4 Hospira, Inc.
- 7.4.1 Aminosyn
- 7.4.2 Liposyn
- 7.5 Otsuka Pharmaceutical Factory Inc.
- 7.5.1 Elneopa
- 7.5.2 Neoparen
- 7.5.3 B-Fluid
- 7.6 Terumo Corporation
- 7.6.1 Unicaliq
- 7.6.2 Fulcaliq
- 8 Parenteral Nutrition Market to 2018 - Competitive Landscape
- 8.1 Market Share Analysis: Parenteral Nutrition
- 8.2 Competitive Profiling
- 8.2.1 Baxter International Inc.
- 8.2.2 B. Braun Melsungen AG
- 8.2.3 Fresenius Kabi AG
- 8.2.4 Hospira, Inc.
- 8.2.5 Otsuka Pharmaceutical Factory Inc.
- 8.2.6 Terumo Corporation
- 9 Parenteral Nutrition Market to 2018 - Strategic Consolidations
- 9.1 Overview
- 9.2 Major Acquisitions in the Parenteral Nutrition Market
- 9.2.1 Baxter International Completes Acquisition of Prism Pharma for $338m in April 2011
- 9.2.2 Baxter Acquires Willow Healthcare Services in July 2009
- 9.2.3 Fresenius Acquires Novartis Nutrition and Nestle Espana in December 2007
- 9.2.4 Fresenius Kabi Acquires Infusia A.S. in December 2004
- 9.2.5 Fresenius Kabi Acquires Clinico GmbH in October 2005
- 9.2.6 Fresenius Kabi Acquires Isotec Nutrition from Alliance Pharmaceuticals in May 2004
- 9.2.7 Hospira Acquires Clayton Manufacturing Facility from Fresenius Kabi in June 2004
- 9.3 Major Agreements in the Parenteral Nutrition Market
- 9.3.1 Baxter Signs Agreement with Hanmi Pharmaceuticals in December 2010
- 9.3.2 Hospira Signs a Five-year Agreement with Novation in October 2010
- 9.3.3 B. Braun Signs Agreement with Amerinet Inc in October 2009
- 9.3.4 B. Braun Signs Agreement with Premier Purchasing Partners in August 2008
- 9.3.5 Hospira Announces New Contract with Premier Purchasing Partners in August 2008
- 9.3.6 Hospira Announces New Contract with HealthTrust Purchasing Group in February 2008
- 9.3.7 Baxter and Novation Sign Two-year Contract Extension in October 2007
- 9.3.8 Baxter Announces Plans to Form Parenteral Nutrition Joint Venture with Baiyunshan in China in August 2007
- 9.3.9 B. Braun Signs Agreement with Curlin Medical in March 2006
- 9.3.10 Fresenius Kabi and Pharmatel Pty Ltd. Formed a Joint Venture in September 2004
- 10 Parenteral Nutrition Market to 2018 - Appendix
- 10.1 Market Definitions
- 10.2 Abbreviations
- 10.3 Bibliography
- 10.4 Research Methodology
- 10.4.1 Coverage
- 10.4.2 Secondary Research
- 10.4.3 Primary Research
- 10.4.4 Section Methodology
- 10.4.5 Expert Panel Validation
- 10.5 Contact Us
- 10.6 Disclaimer
- 1.1 List of Tables
- Table 1: Parenteral Nutrition Market, Global, Nutritional Status Assessment, 2011
- Table 2: Parenteral Nutrition Market, The US, A.S.P.E.N. Guidelines for Parenteral Nutrition, 2004
- Table 3: Parenteral Nutrition Market, Global, Revenues ($m), 2004-2011
- Table 4: Parenteral Nutrition Market, Global, Revenue Forecasts ($m), 2011-2018
- Table 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011
- Table 6: Parenteral Nutrition Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018
- Table 7: Parenteral Nutrition Market, The US, Revenues ($m), 2004-2011
- Table 8: Parenteral Nutrition Market, The US, Revenue Forecasts ($m), 2011-2018
- Table 9: Parenteral Nutrition Market, Top Five Countries of Europe, Revenues ($m), 2004-2011
- Table 10: Parenteral Nutrition Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018
- Table 11: Parenteral Nutrition Market, Japan, Revenues ($m), 2004-2011
- Table 12: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), 2011-2018
- Table 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), 2011
- Table 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), 2011
- Table 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), 2011
- Table 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), 2011
- Table 17: Parenteral Nutrition Market, Global, Product Composition - Lipofundin, 2012
- Table 18: Parenteral Nutrition Market, Global, Product Composition - Aminoplasmal, 2012
- Table 19: Parenteral Nutrition Market, Global, Product Composition - Aminosyn, 2012
- Table 20: Parenteral Nutrition Market, Global, Strategic Consolidations Overview, 2012
- 1.2 List of Figures
- Figure 1: Parenteral Nutrition Market, Global, Nutritional Support Algorithm
- Figure 2: Parenteral Nutrition Market, Global, Nutrition Requirements for TPN, 2012
- Figure 3: Parenteral Nutrition Market, Global, Revenues ($m), 2004-2018
- Figure 4: Parenteral Nutrition Market, Global, Drivers and Barriers, 2012
- Figure 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), 2004-2018
- Figure 6: Parenteral Nutrition Market, The US, Historic Revenue and Forecasts ($m), 2004-2018
- Figure 7: Parenteral Nutrition Market, The US, Key Products, 2012
- Figure 8: Parenteral Nutrition Market, Top Five Countries of Europe, Historic Revenue and Forecasts ($m), 2004-2018
- Figure 9: Parenteral Nutrition Market, Top Five Countries in Europe, Key Products, 2011
- Figure 10: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), 2004-2018
- Figure 11: Parenteral Nutrition Market, Japan, Key Products, 2011
- Figure 12: Parenteral Nutrition Market, Global, Nutrient Market Segmentation (%), 2011
- Figure 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), 2011
- Figure 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), 2011
- Figure 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), 2011
- Figure 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), 2011
- Figure 17: Parenteral Nutrition Market, Global, Product Profile - OLIMEL, 2012
- Figure 18: Parenteral Nutrition Market, Global, Product Profile - Clinimix, 2012
- Figure 19: Parenteral Nutrition Market, Global, Product Profile - ClinOleic 20%, 2012
- Figure 20: Parenteral Nutrition Market, Global, Product Profile - Clinisol 15%, 2012
- Figure 21: Parenteral Nutrition Market, Global, Product Profile - NuTRIflex, 2012
- Figure 22: Parenteral Nutrition Market, Global, Product Profile - Lipofundin, 2012
- Figure 23: Parenteral Nutrition Market, Global, Product Profile - Aminoplasmal, 2012
- Figure 24: Parenteral Nutrition Market, Global, Product Profile - FreAmine III, 2012
- Figure 25: Parenteral Nutrition Market, Global, Product Profile-Intralipid, 2012
- Figure 26: Parenteral Nutrition Market, Global, Product Profile - SmofKabiven, 2012
- Figure 27: Parenteral Nutrition Market, Global, Product Profile - Dipeptiven, 2012
- Figure 28: Parenteral Nutrition Market, Global, Product Profile - Omegaven, 2012
- Figure 29: Parenteral Nutrition Market, Global, Product Profile - Aminosyn, 2012
- Figure 30: Parenteral Nutrition Market, Global, Product Profile - Liposyn, 2012
- Figure 31: Parenteral Nutrition Market, Global, Product Profile - Neoparen, 2012
- Figure 32: Parenteral Nutrition Market, Global, Product Profile - B-Fluid, 2012
- Figure 33: Parenteral Nutrition Market, Global, Product Profile - Unicaliq, 2012
- Figure 34: Parenteral Nutrition Market, Global, Product Profile - Fulcaliq, 2012
- Figure 35: Parenteral Nutrition Market, Global, Market Share of Top Manufacturers (%), 2011
- Figure 36: Parenteral Nutrition Market to 2018, Global, Company Profile - Baxter International Inc., 2012
- Figure 37: Parenteral Nutrition Market, Global, SWOT Analysis - Baxter International Inc., 2012
- Figure 38: Parenteral Nutrition Market to 2018, Global, Company Profile - B. Braun Melsungen AG, 2012
- Figure 39: Parenteral Nutrition Market, Global, SWOT Analysis - B. Braun Melsungen AG, 2012
- Figure 40: Parenteral Nutrition Market, Global, Company Profile - Fresenius Kabi AG, 2012
- Figure 41: Parenteral Nutrition Market, Global, SWOT Analysis - Fresenius Kabi AG, 2012
- Figure 42: Parenteral Nutrition Market, Global, Company Profile - Hospira Inc., 2012
- Figure 43: Parenteral Nutrition Market, Global, SWOT Analysis - Hospira Inc., 2012
- Figure 44: Parenteral Nutrition Market, Global, Company Profile - Otsuka Pharmaceutical Factory Inc., 2012
- Figure 45: Parenteral Nutrition Market, Global, Company Profile - Terumo Corporation, 2012
- Figure 46: Parenteral Nutrition Market, Global, Strategic Consolidations Overview (%), 2012
AbstractParenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth”. It provides in-depth analysis of the market size and drivers and barriers that affect the PN market. The report analyzes the markets for parenteral nutrition in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Sales value is forecast until 2018 for key geographies. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The PN market is rapidly growing with the increasing incidence of diseases such as cancer, AIDS and GI disorders including short bowel syndrome, ischemic bowel disease, pseudo obstruction and Crohn’s disease. The other major factor driving growth of the PN market is an increase in the elderly population in the developed countries. In 2011, the global PN market was estimated to be worth $2.9 billion, representing a CAGR of 6.3% between 2004 and 2011. The US market, with sales worth $1,476m in 2011, accounted for 50.7% of the total PN market. The market in the top five countries in Europe was estimated to be $1,275m, the second largest PN market, and to have grown at a CAGR of 5.4% between 2004 and 2011. The PN market in Japan registered a share of 5.4% of the total PN market, accounting for $157m sales value in 2011.
By 2018, the PN market is forecast to be worth $4,861m, representing a CAGR of 7.6% between 2011 and 2018. The US is expected to remain the largest segment in the PN market with $2,492m of sales in 2018. The PN market in the top five countries in Europe will be the second largest segment with $2,104m in revenues in 2018. Japan, which was the smallest segment in 2011, is expected to register sales value of $265m in 2018, indicating a CAGR of 7.8% between 2011 and 2018. The PN market M&A landscape demonstrated a fairly moderate level of activity between 2004 and 2010, with seven major acquisition deals signed during the time period.
Scope- Annualized market data for the PN market from 2004 to 2011, forecast forward to 2018.
- Analysis of the PN market in the leading geographies of the world, which include the US, the top five countries in Europe (the UK, Germany, France, Italy, Spain) and Japan.
- Market segmentation of the PN market which includes the amino acid, lipids, carbohydrates and additives market in the leading geographies.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of the leading companies. The key companies studied in this report are Baxter, B. Braun, Fresenius Kabi, Hospira, Otsuka Pharmaceutical Factory, Terumo Corporation and Ajinomoto.
- Key M&A activities, licensing agreements that have taken place between 2004 and 2011 in the global PN market.
Reasons to buy- Develop market-entry and market expansion strategies by identifying the leading geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class products with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
